Caio Max Sao Pedro Rocha Lima, Greg Yothers, Thomas J. George, Howard S. Hochster, Hanna Kelly Sanoff, Deirdre J. Cohen, Katherine A. Guthrie, Samuel A. Jacobs, Anwaar Saeed, Scott Kopetz, Linda H. Colangelo, Tanner Freeman, Scott Wesley Cole, Dan Sayam Zuckerman, Theodore S. Hong, Norah Lynn Henry, Patricia A. Ganz, Charles D. Blanke, Norman Wolmark, Michael J. Overman. "Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610.." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.2_suppl.14